作者
John E Piletz, Feyza Aricioglu, Juei-Tang Cheng, Carolyn A Fairbanks, Varda H Gilad, Britta Haenisch, Angelos Halaris, Samin Hong, Jong Eun Lee, Jin Li, Ping Liu, Gerhard J Molderings, Ana Lucia S Rodrigues, Joseph Satriano, Gong Je Seong, George Wilcox, Ning Wu, Gad M Gilad
发表日期
2013/9/1
来源
Drug discovery today
卷号
18
期号
17-18
页码范围
880-893
出版商
Elsevier Current Trends
简介
Highlights
- Sixteen leading groups review evidence for the therapeutic effects of agmatine.
- Agmatine modulatory action at multiple molecular targets is highlighted.
- Challenges and opportunities for the use of agmatine in a spectrum of complex diseases are discussed.
- We focus on the use of agmatine in diabetes mellitus, neurotrauma, opioid action, mood disorders, cognition and cancer.
- Agmatine is poised for expanded drug development efforts and advanced clinical trials.
Agmatine (decarboxylated arginine) has been known as a natural product for over 100 years, but its biosynthesis in humans was left unexplored owing to long-standing controversy. Only recently has the demonstration of agmatine biosynthesis in mammals revived research, indicating its exceptional modulatory action at multiple molecular targets, including neurotransmitter systems, nitric oxide (NO) synthesis and polyamine metabolism, thus …
学术搜索中的文章
JE Piletz, F Aricioglu, JT Cheng, CA Fairbanks… - Drug discovery today, 2013